Name (Synonyms) | Correlation | |
---|---|---|
drug148 | Best Supportive Care Wiki | 1.00 |
drug615 | Ivermectine Wiki | 1.00 |
drug111 | Azithromycin 500 mg Wiki | 1.00 |
drug522 | Hydroxychloroquine Sulfate Wiki | 0.30 |
drug872 | Placebos Wiki | 0.25 |
Name (Synonyms) | Correlation | |
---|---|---|
D055370 | Lung Injury NIH | 0.25 |
D011024 | Pneumonia, Viral NIH | 0.14 |
D013577 | Syndrome NIH | 0.13 |
D055371 | Acute Lung Injury NIH | 0.13 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.13 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.11 |
D011014 | Pneumonia NIH | 0.07 |
There is one clinical trial.
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult patients with Coronavirus Disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Patients will be randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of the patients) or BSC alone (1/3 of the patients). Best supportive care will consist of medical treatment and/or medical interventions per routine hospital practice.